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The role of cytokines in health and disease has received increasing attention and numerous 
investigations have explored the regulation of cytokine gene expression. Tumor necrosis factor- 
a (TNF) has received particular attention because of its central role in septic shock and more 
recent work has shown its participation in transplant immunology. We explored the mechanism 
of cyclosporine A (CsA) modulation of complete Freunds adjuvant macrophage (CFA-MO) TNF 
gene expression. From 0.001 to 1 ug/ml, CsA dose-dependently inhibited Iipopolysaccharide 
(LPS) induced secreted bioactivity; at doses above lOpg/ml CSA was directly toxic to CFA-MO. 
However, them was no suppression of TNF mRNA levels, and CsA also did not inhibit the 
accumulation of cell-associated TNF. Thus, CsA modulates TNF gene expression in a previously 
undescribed manner. Q 1989 Academic Press, Inc. 
TNF is a potent cytokine with diverse pathologic and physiologic effects. In vitro, this 
polypeptide mediator modulates a wide range of activities in multiple cell types (1). Although its 
original description was that of cytolytic activity against murine solid tumors (2), further 
investigations have shown TNF to play a major role in the pathophysiology of several disease 
states. TNF has been extensively studied in recent years because of the central role of this 
mediator in septic shock (3), its participation in the pathophysiology of AIDS (4) and its role in 
transplant immunology, including both graft-versus-host disease (5) and allograft rejection (6). 
Elevated plasma levels of TNF have been detected in several clinical conditions including 
patients with septic shock (7), patients with parasitic infections (8), and patients actively 
rejecting renal allografts (6). The latter clinical study is of particular interest, as none of the 
patients in this transplantation study were receiving CsA. In animal studies, TNF has been 
shown to be an active mediator in the pathogenesis of mutine cerebral malaria (9), and CsA 
demonstrated a protective effect in this experimental model (10). Additionally, CsA has been 
shown to inhibit TNF production by human peripheral blood monocytes (11). Data presented in 
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the following studies demonstrate that CsA can decrease the production of extracellular TNF 
bioactivity without decreasing TNF mRNA, or the accumulation of intracellular TNF bioactivity. 
Materials and Methods 
Preparation of cells: Macrophages were elicited in CBA/J mice (Jackson Labs, Bar Harbor ME) 
by the intraperitoneal injection of CFA mixed 1:l with normal saline. Two weeks later the cells 
were harvested and resuspended in complete media ([CM] RPMI 1640 with 2 mM L-glutamine, 
25 mM HEPES and 1% penicillin-streptomycin [whittaker Bioproducts, Walkersville MD]). 
The cells were adhered for 1 hour in 35 mm or 100 mm tissue culture plates (Costar, Cambridge 
MA), pretreated for 30 minutes with the indicated doses of CsA (Sandoz) and then challenged 
with the indicated doses of LPS (E. coli 011 l:B4, Sigma Chemical Co. St. Louis, MO). 
Tumor necrosis assay: TNF bioactivity was measured in the WEHI 164 subclone 13 bioassay, as 
previously described (12). Briefly, samples were serially diluted in 96 well flat bottom plates in 
CM plus 1% fetal calf serum (FCS). WEHJ cells were resuspended in CM with 10% FCS, 0.5 
u&l actinomycin D (Calbiochem, La Jolla CA), added to the cells and the plates incubated 
overnight at 370C in 5% CO2/95% air. Twenty ul of MIT-tertazolium (Sigma) were added to 
each well, the plates incubated an additional 4 hours and the crystals dissolved with 0.04N HCl 
in isopropanol. 
Viabilitv: The viability of the adherent CFA-MO was established by removing the supematant 
media and adding back an additional 1 ml of CM with 50 ul of M’lT-temuolium and allowing 
the plates to incubate 4 hours. The crystals were dissolved as above, and read 
spectrophotometrically at 550 nm. The cells which received neither LPS nor CsA was assigned 
a viability of 100%. 
Northern blot analvsis: RNA was isolated from the CFA-MO three hours after LPS since this is 
the time of peak TNF specific mRNA. RNA was isolated by a modification of the method of 
Chirgwin et at (13) and Jonas et al (14) as previously described (15). The cells were overlaid 
with a solution of 25 mM Tris-HCl, pH 8.0, 4.2 M guanidine isothiocyanate, 0.1 M 2 
mercaptoethanol and 0.5% Sarkosyl. Cells were scraped, pipetted into a RNAse free tube and an 
equal volume of 100 mM Tris-HCl, pH 8.0, 10 mM EDTA and 1% SDS added. The RNA was 
then extracted with chloroform-phenol, chloroform-isoamyl alcohol and alcohol precipitated. 
This RNA was then electrophoresed in formaldehyde/l% agarose gels, transblotted to 
nitrocellulose, baked and prehybridized. The blots were then hybridized with a 32P end labeled 
probe specific for TNF, 5’-GGT-CAC-CCT-TCT-CCA-GCT-GGA-AGA-C-3’ (16). The blot 
was then stripped and reprobed for B-a&n mRNA using 5’-GGC-TGG-GGT-G’IT-GAA-GGT- 
CT%-AAA-CAT-GAT-CTG-GGT-CAT-CIT-3’ (17). (Probes were the generous gifts of Dr. 
Glen Andrews and Henry Showell, Pfizer Pharmaceutical Co. Groton CT). 
Results 
Our first studies examined the ability of CsA to inhibit cell viability at doses from 0.001 
to 100 ugknl. Figure 1 shows that CSA did not decrease cell viability below a concentration of 1 
pghl, while, at 10 ug/ml and above, CsA was directly toxic to the cells. In our next studies, we 
evaluated the ability of CsA to dose dependently suppress lipopolysaccharide (LPS) induced 
TNF production. As shown in Figure 2, CsA dose dependently suppressed TNF production in 
response to either 100 rig/ml or 10 ug/ml of LPS. This TNF production was assessed at 6 hours 
post LPS challenge since this represented the peak of bioactivity in macrophage supematants 
(15). 
In contrast to the reduction in the secretion of TNF biological activity, CsA had no effect 
on the levels of TNF mRNA (Figure 3). The addition of CsA (.OOl to 1 u&nl) did not alter the 
accumulation of TNF mRNA, while the supematants of these same cultures again showed a dose 
dependent decrease in the secreted bioactivity. These studies demonsuated that CsA inhibited 
the production of supematant bioactivity without decreasing mRNA. To further evaluate the 
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Figure 1. CsA toxicity to CFA-MO. CsA was added at the indicated doses and 30 minutes 
later all cultures were challenged with 10 ug/ml LPS. The viability was 
determined 6 hours after the LPS. CsA at 10 and 100 ug/ml markedly decreased 
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Figure 2. Dose-dependent CsA inhibition of TNF supematant bioactivity. CsA dose 
dependently suppressed TNF secreted bioactivity when the cells are challenged 
with either 100 rig/ml (A) or 10 ug/ml (B) LPS. The supematants were collected 
6 hours after LPS challenge. Each value is the mean + SEM for triplicate 
measurements. 
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Figure 3. Northern blot of failure of CsA to inhibit TNF mRNA. Cells were treated as in 
Figure 2, except the RNA was isolated after 3 hours, at the peak of TNF mRNA 
accumulation. The cells were challenged with 100 @ml of LPS. CsA failed to 
inhibit TNF mRNA accumulation at any dose, but there was no effect on B-actin 
accumulation. The upper panel is the blot probed for TNF, the lower panel is the 
blot stripped and then reprobed for B-actin. C is control, cells which did not 
receive CsA or LPS. 
level of TNF regulation, cell-associated TNF levels were measured, to assess whether there was 
failure of translation or blockade in the secretion of cell-associated TNF. Table 1 provides data 
that the cell-associated levels, either 3 or 6 hours post LPS, are not decreased by CsA treaanent, 
but supematant bioactivity is suppressed. 





Cellular Supematant Total 
.037+/-.005 .153+/-.006 .233+.07 1 
5.28+/-.87 39.72+/- 11.35 52.78+/-12.14 





Cellular Supematant Total 
.193+/-.043 .218+/-.07 .427+.12 
7.03+/-.65 97.4+/-3.15 102.27+/-2.86 
5.47+/-.32 8.12+/-2.76* 15.76+/-2.61* 
The CFA-MO cells were pretreated with 1 @ml CsA for 30 minutes, then stimulated with LPS. 
At the indicated time the cells were scraped, resuspended in 2 ml of CM and frozen and thawed 
3 times. Each value is the mean +/-SEM of the TNF units/ml for 3 determinations. 
* = ~~0.05 compared to LPS by Students t-test. 
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Discussion 
Collectively, these data demonstrate that CsA is effective in inhibiting TNF production 
without depressing cell-associated TNF levels or decreasing TNF mRNA. Therefore, this 
inhibition by CsA represents a different mechanism than that observed with either 
dexamethasone (18) or prostaglandin E2(PGE2) (15). Specifically, CsA can suppress TNF 
production without decreasing TNF mRNA, while either dexamethasone or PGE2 block TNF 
transcription” These studies show that the regulation of TNF gene expression by CsA is 
complex, and it is possible that there is a partial blockade of both translation and secretion of 
TNF. Alternatively, the intracellular levels may be under different regulatory mechanisms, such 
that at a certain intracellular level TNF inhibits its own translation, and CsA only blocks at the 
level of secretion. Additionally, a mechanism of regulation is defined that differs from that 
observed for interleukin 2, where CsA has been demonstrated to suppress lymphocyte production 
of IL-2 at the level of mRNA (19). This differential regulation may have implications in 
transplant therapy, since it would be possible for a patient to have a pool of TNF mRNA 
available for rapid translation, even with theraputic levels of CSA. 
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